Лучшие больницы для «Gaucher Disease Treatment» в Дубай, ОАЭ

Gaucher disease is the most prevalent lysosomal storage disorder worldwide, resulting from autosomal recessive mutations in the GBA gene encoding the enzyme acid beta-glucocerebrosidase (glucocerebrosidase). The enzymatic deficiency causes progressive accumulation of glucosylceramide (glucocerebroside) within tissue macrophages — termed Gaucher cells — predominantly in the reticuloendothelial system. This pathological lipid burden drives multisystem organ dysfunction characterized by massive hepatosplenomegaly, pancytopenia (anemia, thrombocytopenia, leukopenia), debilitating bone disease including avascular necrosis and pathological fractures, and in neuronopathic subtypes (Type 2 and Type 3), progressive neurological deterioration including oculomotor apraxia, ataxia, and cognitive decline.

• ELIGIBLE PATIENTS:
• Confirmed diagnosis of Gaucher disease by demonstration of deficient leukocyte glucocerebrosidase enzyme activity (typically <15% of mean normal) AND/OR identification of pathogenic bi-allelic GBA gene mutations on molecular genetic testing
• Patients with symptomatic Type 1 Gaucher disease: significant splenomegaly (>5x normal volume by MRI volumetry), hepatomegaly (>1.25x normal), thrombocytopenia (<120,000/µL), anemia (Hb <11g/dL in women, <12g/dL in men), or active bone disease including bone marrow infiltration on MRI or DEXA-confirmed osteoporosis
• Type 3 patients with visceral and/or skeletal disease amenable to ERT (neurological manifestations have limited response but systemic disease can be controlled)
• Patients with eliglustat CYP2D6 metabolizer status confirmed (extensive, intermediate, or poor metabolizers eligible; ERT preferred for ultra-rapid metabolizers)
• +20 more

Enzyme Replacement Therapy (ERT) — THE First-line STANDARD:

ERT represents the cornerstone of disease-modifying treatment for symptomatic Type 1 and Type 3 Gaucher disease. Three recombinant glucocerebrosidase preparations are approved and available at major centers in India and the UAE:

1. Imiglucerase (Cerezyme, Sanofi Genzyme): The original and most extensively studied ERT, produced in CHO cells. Administered intravenously at 60 U/kg every two weeks (high dose) or 30 U/kg every two weeks (maintenance). Standard infusion duration is 1–2 hours under nursing supervision. The Gaucher Registry (ICGG) comprising over 6,000 patients demonstrates consistent improvements in hemoglobin (mean +2.0 g/dL over 2 years), platelet counts (+50–100%), spleen volume reduction (>50% at 2 years), and liver volume reduction (>25% at 2 years) with sustained therapy.

2. Velaglucerase alfa (VPRIV, Takeda): A human cell-line-derived ERT (HT-1080 fibroblast production) with higher mannose content, potentially improving macrophage targeting. Offers a comparable efficacy and safety profile to imiglucerase with demonstrated utility as a switch agent for patients developing hypersensitivity or suboptimal response to imiglucerase.

PHASE 1 — PRE-ARRIVAL PREPARATION (4–6 weeks before travel):

• GAF Healthcare coordinates remote pre-consultation with the specialist metabolic/lysosomal storage disorder team via secure video telemedicine
• Patient submits all prior medical records: enzyme assay results, GBA genetic reports, prior treatment records, MRI volumetry reports, DEXA scans, current medication list
• GAF case manager compiles a structured medical summary and submits to the treating physician
• Specialist reviews records, confirms diagnosis, determines treatment-naive vs. switch therapy status, and requests any outstanding investigations
• Pharmacogenomic CYP2D6 testing arranged locally or remotely if SRT (eliglustat) is being considered
• Visa application assistance initiated: e-Medical Visa for India (typically processed within 3–5 business days), UAE entry visa coordination for eligible nationalities
• Travel insurance guidance and pre-travel health briefing provided

PHASE 2 — ARRIVAL AND COMPREHENSIVE EVALUATION (Days 1–3):